What We're Reading: Page 109
Industry reads hand-picked by our editors
Aug 09, 2022
-
Boston Business Journal
Biogen seeks to shrink real estate in Kendall Square, suburbs
-
Politico
Monkeypox dose sparing? Biden admin looks to NIH-funded study for clues.
-
FierceBiotech
Genentech tries again on diversity aim for Alzheimer’s program
Aug 08, 2022
Aug 05, 2022
-
Bloomberg
Alphabet’s DeepMind Shows AI’s Value in Speeding Drug Discovery
-
Reuters
China’s Innovent Biologics secures over $300 million investment from Sanofi
-
Politico
Pharma group leader says Dems who vote for reconciliation bill ‘won’t get a free pass’
-
Nature
Billions more for US science: how the landmark spending plan will boost research
Aug 04, 2022
-
Bloomberg
Global Blood Therapeutics Is Said to Draw Takeover Interest
-
The Wall Street Journal
Eli Lilly’s Covid-19 Antibody Treatment to Be Sold Commercially
-
FiercePharma
Thermo Fisher marches on with $650M bioprocessing expansion
Aug 03, 2022
-
Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars
-
STAT
AbbVie’s ‘patent thickets’ for Humira don’t thwart competition, court rules
-
The Wall Street Journal
Moderna Profit Falls Amid Charges for Unused Covid-19 Vaccines
-
FierceBiotech
Genentech, AC Immune reveal more about crenezumab failure
Aug 02, 2022
-
The Seattle Times
Clay Siegall built Seattle biotech firm Seagen into a $1.6B giant. Then the cops came calling
-
ProPublica
After Receiving Millions in Drug Company Payments, Pain Doctor Settles Federal Kickback Allegations
-
The Washington Post
Biden names FEMA’s Robert Fenton as monkeypox response coordinator
-
STAT
Cities are lobbying to host ARPA-H. Experts don’t understand why
Aug 01, 2022
-
The Washington Post
‘Not enough shots’: U.S. faces ‘vaccine cliff’ on monkeypox
-
The Wall Street Journal
Amgen Fights IRS Over $10.7 Billion Tax Bill
-
NPR
Alzheimer’s researchers are looking beyond plaques and tangles for new treatments
-
Fierce Biotech
FDA’s Califf backs limited use of single-arm trials, but says regulatory pathways for some cancers should ‘move into a new phase’
Previous
